Rational Pharmacotherapy in Cardiology

Advanced search

Treatment of Hypertension: Is There a Place for Personalization of the Approach in Modern Recommendations?

Full Text:


The important result of the revision of the European and Russian guidelines for the management of arterial hypertension was a conclusion about the need to use a double combination of antihypertensive drugs as the first stage of antihypertensive therapy. The review presents benefits of combined antihypertensive therapy, confirmed by the results of randomized clinical trials and meta-analysis. There are literature data suggesting one of the first line reasonable combinations is the combination of angiotensin converting enzyme inhibitors (ACEI) and thiazide-like diuretic. The article discusses the benefits of single-pill combinations before free ones, such as increase in patient adherence to long-term treatment, reduction in the cost of the drug and the number of tablets. As an example, a highly effective single-pill combination of one of the most used ACEI, lisinopril and indapamide sustained release, is considered, which has protective activity, vasodilator properties and metabolic neutrality. The article presents the data of the PIFAGOR IV study that indapamide is the most widely used diuretic in Russia, which is characterized by high antihypertensive efficacy, good tolerance, cardioprotective, nephroprotective and osteoprotective properties. The results of large-scale studies, which show the ability of lisinopril to retain target blood pressure level, antiproteinuric and cardioprotective activity, are also presented. This single-pill combination has a long additive effect, contributing to reliable daily monitoring of blood pressure. The authors expressed the opinion that the prescription of highly effective single-pill combinations will contribute to organ protection and reduce the risk of cardiovascular complications development.

About the Authors

V. I. Podzolkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Valery I. Podzolkov - MD, PhD, Professor, Head of Chair of Faculty Therapy №2, Director of Therapeutic Clinic, University Clinical Hospital №4, Sechenov University.

Trubetskaya ul. 8-2, Moscow, 119991.

A. E. Bragina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Anna E. Bragina - MD, PhD, Professor, Chair of Faculty Therapy №2, Sechenov University.

Trubetskaya ul. 8-2, Moscow, 119991.

Yu. N. Rodionova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Yulia N. Rodionova - MD, PhD, Assistant, Chair of Faculty Therapy №2, Sechenov University.

Trubetskayaul. 8-2, Moscow, 119991.


1. Boytsov S.A., Balanova Y.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ESSE-RF. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-2014-4-4-14.

2. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021-104. DOI:10.1093/eurheartj/ehy339.

3. Clinical guidelines of the Ministry of Health of the Russian Federation. Arterial hypertension in adults [cited by Jan 04, 2020]. Available from:!/recomend/687 (In Russ.)

4. Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V., et al. The prevalence of non-infectious diseases risk factors in russian population in 2012-2013 years. The results of ESSE-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11 (In Russ.) DOI:10.15829/1728-8800-2014-6-4-11.

5. Shamliyan T., Talley K.M., Ramakrishnan R., Kane R.L. Association of frailty with survival: a systematic literature review. Ageing Res Rev. 2013;12(2):719-36.

6. Bakris G.L. The importance of blood pressure control in the patient with diabetes Am J Med. 2004;116(5) suppl 1:30-8. DOI:10.1016/j.amjmed.2003.10.018.

7. Leonova M.V., Steinberg L.L., Belousov Y.B., et al. Results of pharmacoepidemiologic study of arterial hypertension PIFAGOR IV: physicians compliance. Russian Journal of Cardiology. 2015;(1):59-66 (In Russ.) DOI:10.15829/1560-4071-2015-1-59-66.

8. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. DOI:10.1016/j.jacc.2017.11.006.

9. Hypertension in adults: diagnosis and management NICE guideline Published: 28 August 2019 [cited by Jan 04, 2020]. Available from:

10. Rotar O.P., Libis R.A., Isaeva E.N., et al. Metabolic syndrome prevalence in russian cities. Russian Journal of Cardiology. 2012;(2):55-62 (In Russ.) DOI:10.15829/1560-4071-2012-2-55-62.

11. Burniera M., Bakris G., Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens. 2019;37(8):1574-86. DOI:10.1097/HJH.0000000000002088.

12. Podzolkov V.I. Arterial hypertension. Moscow: Media News Agency; 2016 (In Russ.)

13. Qi H., Liu Z., Cao H., et al. Comparative efficacy of antihypertensive agents in salt-sensitive hypertensive patients: a network meta-analysis. Am J Hypertens. 2018;31(7):835-46. DOI:10.1093/ajh/hpy027.

14. Jeppesen J., Hansen T.W., Rasmussen S., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49(21):2112-9. DOI:10.1016/j.jacc.2007.01.088.

15. Rogowski O., Steinvil A., Berliner S., et al. Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol. 2009;8:55. DOI:10.1186/1475-2840-8-55.

16. Palatini P., Dorigatti F., Zaetta V., et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24(9):1873-80. DOI:10.1097/01.hjh.0000242413.96277.5b.

17. Makani H., Bangalore S., Romero J., et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate - a meta-analysis of randomized trials. J Hypertens. 2011;29(7): 1270-80. DOI:10.1097/HJH.0b013e3283472643.

18. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL- HAT). JAMA. 2002;288(23):2981-97. DOI:10.1001/jama.288.23.2981.

19. Cavalieri L., Cremonesi G. Delapril plus Indapamide: A Review of the Combination in the Treatment of Hypertension. Clin Drug Investig. 2007;27(6):367-80. DOI:10.2165/00044011-200727060-00001.

20. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomized double-blind studies. Drug Saf. 2001;24(15):1155-65. DOI:10.2165/00002018-200124150-00006.

21. Kuo S.W., Pei-Dee, Hung Y.J., et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens. 2003;16(8):623-8. DOI:10.1016/s0895-7061(03) 00896-3.

22. Martins M.C., Meyers A.M., Whalley N.A., et al. Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. Br J Urol. 1996;78(2):176-80. DOI:10.1046/j.1464-410x.1996.00633.x.

23. Lalande A., Roux C., Graulet A.M., et al. The diuretic indapamide increases bone mass and decreases bone resorption in spontaneously hypertensive rats supplemented with sodium. J Bone Miner Res. 1998;13(9):1444-50. DOI:10.1359/jbmr.1998.13.9.1444.

24. Lalande A., Roux S., Denne M.A., et al. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res. 2001;16(2):361-70. DOI:10.1359/jbmr.2001.16.2.361.

25. Musini V.M. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;29 (5):CD003824. DOI:10.1002/14651858.CD003824.pub2.

26. Marre M., Puig J.G., Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR study. J Hypertens. 2004;22:1613-22. DOI:10.1097/01.hjh.0000133733.32125.09.

27. Gosse P., Sheridan D.J., Zannad F., et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18(10):1465-75. DOI:10.1097/00004872-200018100-00015.

28. Beckett N.S., Peters R., Fletcher A.E., et al.; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98. DOI:10.1056/NEJ-Moa0801369.

29. Tomaszewski M., White C., Patel P., et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855-61. DOI:10.1136/heartjnl-2013-305063.

30. Gupta A., Poulter N. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive drugs: a meta-analysis. Hypertension. 2010;55:399-407. DOI:10.1161/HYPERTENSION-AHA.109.139816.

31. Kishore S.P., Salam A., Rodgers A., et al. Fixed-dose combinations for hypertension. Lancet. 2018;392(10150):819-820. DOI:10.1016/S0140-6736(18)31814-2.

32. James P.A., Oparil S., Carter B.L., et al. 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. DOI:10.1001/jama.2013.284427.

33. Malacco E., Santonastaso M., Vari N.A., et al. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004;26(6):855-65. DOI:10.1016/s0149-2918(04)90129-4.

34. Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus HCTZ in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in obese Patients with Hypertension (TROPHY) Study Group. Hypertension. 1997;30(1 Pt 1):140-5. DOI:10.1161/01.hyp.30.1.140.

35. Mancia G., Zanchetti A., Agabiti-Rosei E., et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997;95(6):1464-70. DOI:10.1161/01.cir.95.6.1464.

36. Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19(2):303-9. DOI:10.1097/00004872-200102000-00018.

37. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274): 1440-4. DOI:10.1136/bmj.321.7274.1440.

38. Chaturvedi N., Sjolie A.K., Stephenson J.M., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28-31. DOI:10.1016/s0140-6736(97)06209-0.

39. Savenkov M.P., Ivanov S.N., Mikhaylusova M.P., et al. The Study of the Fixed Dose Combination of Lisinopril with Prolonged Indopamide (FIXLINDA) with Daily Blood Pressure Monitoring and Diuresis in Hypertensive Patients. Rational Pharmacotherapy in Cardiology. 2019;15(4):510-7 (In Russ.) DOI:10.20996/1819-6446-2019-15-4-510-517.

40. Podzolkov V.I., Tarzimanova A.I., Georgadze Z.O. Modern Principles of Treatment of Uncontrolled Hypertension. Rational Pharmacotherapy in Cardiology 2019;15(5):736-41 (In Russ.) DOI:10.20996/1819-6446-2019-15-5-736-741.

For citation:

Podzolkov V.I., Bragina A.E., Rodionova Y.N. Treatment of Hypertension: Is There a Place for Personalization of the Approach in Modern Recommendations? Rational Pharmacotherapy in Cardiology. 2020;16(3):449-456. (In Russ.)

Views: 64

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)